A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissue

Pauline J Carder, Claire E Murphy, Peter Dervan, Maria Kennedy, Amanda McCann, Philippa T K Saunders, Abeer M Shaaban, Christopher S Foster, Caroline J Witton, John M S Bartlett, Rosemary A Walker, Valerie Speirs

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Estrogen receptor (ER) alpha is a well-established independent prognostic factor in breast cancer whose presence determines the clinical implications of adjuvant endocrine therapy. A second receptor, ERb has been described, and a number of studies have examined its expression in breast tissue. However elucidation of the role played by ERb has been hampered by published immunohistochemical studies employing a variety of protocols and scoring systems such that inter-laboratory comparisons are difficult. Here we present a multi-centre study designed to critically evaluate inter-laboratory differences in methodology. Six UK and Irish centres participated in this study. A small series of breast cancers were stained using centre-specific laboratory protocols and scored using both centrespecific and standard scoring protocols. There was generally poor agreement as to what constituted a positive or negative case when centre-specific scoring systems were used with less than half of all cases in agreement. Concordance was improved when a standard scoring system was used but varied according to threshold for positivity employed and primary antibody. Our results emphasise the need for further studies addressing the role of ERb to be based on a wider consensus on criteria for positivity. Ideally this should be based on calibration against clinical outcome.

Original languageEnglish
Pages (from-to)287-93
Number of pages7
JournalBreast Cancer Research and Treatment
Volume92
Issue number3
DOIs
Publication statusPublished - Aug 2005

Fingerprint

Estrogen Receptor beta
Paraffin
Formaldehyde
Breast
Breast Neoplasms
Estrogen Receptor alpha
Calibration
Antibodies
Therapeutics

Keywords

  • Breast Neoplasms
  • Estrogen Receptor beta
  • Female
  • Histocytological Preparation Techniques
  • Humans
  • Immunohistochemistry
  • Interinstitutional Relations
  • Ireland
  • Laboratories
  • Pilot Projects
  • Reference Standards
  • United Kingdom
  • Comparative Study
  • Journal Article
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

Cite this

A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissue. / Carder, Pauline J; Murphy, Claire E; Dervan, Peter; Kennedy, Maria; McCann, Amanda; Saunders, Philippa T K; Shaaban, Abeer M; Foster, Christopher S; Witton, Caroline J; Bartlett, John M S; Walker, Rosemary A; Speirs, Valerie.

In: Breast Cancer Research and Treatment, Vol. 92, No. 3, 08.2005, p. 287-93.

Research output: Contribution to journalArticle

Carder, PJ, Murphy, CE, Dervan, P, Kennedy, M, McCann, A, Saunders, PTK, Shaaban, AM, Foster, CS, Witton, CJ, Bartlett, JMS, Walker, RA & Speirs, V 2005, 'A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissue', Breast Cancer Research and Treatment, vol. 92, no. 3, pp. 287-93. https://doi.org/10.1007/s10549-004-4262-8
Carder, Pauline J ; Murphy, Claire E ; Dervan, Peter ; Kennedy, Maria ; McCann, Amanda ; Saunders, Philippa T K ; Shaaban, Abeer M ; Foster, Christopher S ; Witton, Caroline J ; Bartlett, John M S ; Walker, Rosemary A ; Speirs, Valerie. / A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissue. In: Breast Cancer Research and Treatment. 2005 ; Vol. 92, No. 3. pp. 287-93.
@article{c7e2c4f5c66042959f2e0947afcc6c81,
title = "A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissue",
abstract = "Estrogen receptor (ER) alpha is a well-established independent prognostic factor in breast cancer whose presence determines the clinical implications of adjuvant endocrine therapy. A second receptor, ERb has been described, and a number of studies have examined its expression in breast tissue. However elucidation of the role played by ERb has been hampered by published immunohistochemical studies employing a variety of protocols and scoring systems such that inter-laboratory comparisons are difficult. Here we present a multi-centre study designed to critically evaluate inter-laboratory differences in methodology. Six UK and Irish centres participated in this study. A small series of breast cancers were stained using centre-specific laboratory protocols and scored using both centrespecific and standard scoring protocols. There was generally poor agreement as to what constituted a positive or negative case when centre-specific scoring systems were used with less than half of all cases in agreement. Concordance was improved when a standard scoring system was used but varied according to threshold for positivity employed and primary antibody. Our results emphasise the need for further studies addressing the role of ERb to be based on a wider consensus on criteria for positivity. Ideally this should be based on calibration against clinical outcome.",
keywords = "Breast Neoplasms, Estrogen Receptor beta, Female, Histocytological Preparation Techniques, Humans, Immunohistochemistry, Interinstitutional Relations, Ireland, Laboratories, Pilot Projects, Reference Standards, United Kingdom, Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't",
author = "Carder, {Pauline J} and Murphy, {Claire E} and Peter Dervan and Maria Kennedy and Amanda McCann and Saunders, {Philippa T K} and Shaaban, {Abeer M} and Foster, {Christopher S} and Witton, {Caroline J} and Bartlett, {John M S} and Walker, {Rosemary A} and Valerie Speirs",
year = "2005",
month = "8",
doi = "10.1007/s10549-004-4262-8",
language = "English",
volume = "92",
pages = "287--93",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissue

AU - Carder, Pauline J

AU - Murphy, Claire E

AU - Dervan, Peter

AU - Kennedy, Maria

AU - McCann, Amanda

AU - Saunders, Philippa T K

AU - Shaaban, Abeer M

AU - Foster, Christopher S

AU - Witton, Caroline J

AU - Bartlett, John M S

AU - Walker, Rosemary A

AU - Speirs, Valerie

PY - 2005/8

Y1 - 2005/8

N2 - Estrogen receptor (ER) alpha is a well-established independent prognostic factor in breast cancer whose presence determines the clinical implications of adjuvant endocrine therapy. A second receptor, ERb has been described, and a number of studies have examined its expression in breast tissue. However elucidation of the role played by ERb has been hampered by published immunohistochemical studies employing a variety of protocols and scoring systems such that inter-laboratory comparisons are difficult. Here we present a multi-centre study designed to critically evaluate inter-laboratory differences in methodology. Six UK and Irish centres participated in this study. A small series of breast cancers were stained using centre-specific laboratory protocols and scored using both centrespecific and standard scoring protocols. There was generally poor agreement as to what constituted a positive or negative case when centre-specific scoring systems were used with less than half of all cases in agreement. Concordance was improved when a standard scoring system was used but varied according to threshold for positivity employed and primary antibody. Our results emphasise the need for further studies addressing the role of ERb to be based on a wider consensus on criteria for positivity. Ideally this should be based on calibration against clinical outcome.

AB - Estrogen receptor (ER) alpha is a well-established independent prognostic factor in breast cancer whose presence determines the clinical implications of adjuvant endocrine therapy. A second receptor, ERb has been described, and a number of studies have examined its expression in breast tissue. However elucidation of the role played by ERb has been hampered by published immunohistochemical studies employing a variety of protocols and scoring systems such that inter-laboratory comparisons are difficult. Here we present a multi-centre study designed to critically evaluate inter-laboratory differences in methodology. Six UK and Irish centres participated in this study. A small series of breast cancers were stained using centre-specific laboratory protocols and scored using both centrespecific and standard scoring protocols. There was generally poor agreement as to what constituted a positive or negative case when centre-specific scoring systems were used with less than half of all cases in agreement. Concordance was improved when a standard scoring system was used but varied according to threshold for positivity employed and primary antibody. Our results emphasise the need for further studies addressing the role of ERb to be based on a wider consensus on criteria for positivity. Ideally this should be based on calibration against clinical outcome.

KW - Breast Neoplasms

KW - Estrogen Receptor beta

KW - Female

KW - Histocytological Preparation Techniques

KW - Humans

KW - Immunohistochemistry

KW - Interinstitutional Relations

KW - Ireland

KW - Laboratories

KW - Pilot Projects

KW - Reference Standards

KW - United Kingdom

KW - Comparative Study

KW - Journal Article

KW - Multicenter Study

KW - Research Support, Non-U.S. Gov't

U2 - 10.1007/s10549-004-4262-8

DO - 10.1007/s10549-004-4262-8

M3 - Article

VL - 92

SP - 287

EP - 293

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -